ICU Medical (NASDAQ:ICUI) Price Target Raised to $195.00 at Piper Sandler

ICU Medical (NASDAQ:ICUI) had its target price hoisted by research analysts at Piper Sandler from $163.00 to $195.00 in a research report issued on Friday,Benzinga reports. The firm currently has an “overweight” rating on the medical instruments supplier’s stock. Piper Sandler’s price target suggests a potential upside of 6.74% from the company’s current price.

Several other brokerages also recently commented on ICUI. Jefferies Financial Group raised ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Needham & Company LLC raised their price target on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a report on Friday. Sanford C. Bernstein lowered ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, KeyCorp raised their target price on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research note on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $192.80.

ICU Medical Price Performance

Shares of ICU Medical stock traded up $16.32 during mid-day trading on Friday, reaching $182.69. 415,657 shares of the stock were exchanged, compared to its average volume of 292,713. ICU Medical has a fifty-two week low of $107.00 and a fifty-two week high of $192.85. The company has a market cap of $4.57 billion, a price-to-earnings ratio of 99.11, a price-to-earnings-growth ratio of 2.32 and a beta of 0.74. The firm has a 50-day simple moving average of $150.66 and a 200 day simple moving average of $140.72. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. The firm had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The company’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the previous year, the business earned $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, sell-side analysts predict that ICU Medical will post 6.51 EPS for the current fiscal year.

Insider Buying and Selling at ICU Medical

In other news, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the transaction, the director owned 7,960 shares of the company’s stock, valued at $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the transaction, the vice president owned 19,460 shares in the company, valued at approximately $2,414,596.80. This represents a 11.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

A number of institutional investors and hedge funds have recently modified their holdings of the business. Norges Bank acquired a new position in shares of ICU Medical during the 4th quarter worth about $58,083,000. Kirr Marbach & Co. LLC IN boosted its stake in ICU Medical by 18.4% during the 1st quarter. Kirr Marbach & Co. LLC IN now owns 44,153 shares of the medical instruments supplier’s stock worth $5,702,000 after acquiring an additional 6,863 shares during the last quarter. F m Investments LLC grew its holdings in ICU Medical by 33.3% during the fourth quarter. F m Investments LLC now owns 46,519 shares of the medical instruments supplier’s stock valued at $6,637,000 after purchasing an additional 11,608 shares during the period. Thrivent Financial for Lutherans grew its holdings in ICU Medical by 1,604.0% during the fourth quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock valued at $43,294,000 after purchasing an additional 285,648 shares during the period. Finally, Fifth Third Bancorp increased its stake in ICU Medical by 26,365.6% in the first quarter. Fifth Third Bancorp now owns 43,139 shares of the medical instruments supplier’s stock valued at $5,571,000 after purchasing an additional 42,976 shares in the last quarter. 96.10% of the stock is owned by institutional investors.

Key Headlines Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat estimates. ICU Medical reported adjusted earnings of $2.37 per share, well above the $1.91 consensus estimate and up from $2.10 a year earlier. Revenue of $547.88 million also exceeded expectations of $533.44 million. ICU Medical Q2 earnings report
• Positive Sentiment: Full-year guidance was raised above Wall Street expectations. ICU Medical now expects fiscal 2026 earnings of $8.60 to $9.00 per share, compared with the prior consensus estimate of $7.83. The improved outlook signals management expects continued earnings momentum. ICU Medical second-quarter results and guidance
• Positive Sentiment: Analysts responded by lifting their forecasts. Needham raised its price target from $165 to $187 and upgraded the stock to “Buy.” Other analysts also increased targets following the earnings beat and stronger guidance. Analyst forecasts following ICU Medical earnings
• Neutral Sentiment: Revenue growth remained modest. Second-quarter revenue increased only about 0.5% year over year, while the stock’s elevated valuation—approximately 100 times earnings—may limit additional upside despite the improved outlook. Needham’s new target also implies only limited near-term appreciation from recent trading levels.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.